The value of immunohistochemistry as a diagnostic aid in ovarian neoplasia: A review

Pathology Case Reviews

Volumn 11, Issue 1, 2006, Pages 31-37

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Differential diagnosis; Immunohistochemistry; Ovary

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; BETA CATENIN; CA 125 ANTIGEN; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; INHIBIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR CDX2; VILLIN;

ADNEXA DISEASE; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPITHELIUM CELL; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MESONEPHROMA; MESOTHELIUM CELL; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVARY METASTASIS; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SEX CORD TUMOR; UTERINE SEROUS CARCINOMA; WART VIRUS;

EID: 33746613697     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/01.pcr.0000197427.42151.a2     Document Type: Review

References (70)

1. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology. 2002;40:309-326.
2. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol. 2000;53:327-334.
3. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001;20:64-78.
4. Marjoniemi VM. Immunohistochemistry in gynaecological pathology: a review. Pathology. 2004;36:109-119.
5. Wauters CC, Smedts F, Gerrits LG, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995;26:852-855.
6. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497.
7. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429.
8. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
9. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-1085.
10. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
11. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43:151-156.
12. Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol. 2004;23:52-57.
13. Tornillo L, Moch H, Diener PA, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol. 2004;57:641-643.
14. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal)mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol. 2004;12:127-131.
15. Guerrieri C, Franlund B, Fristedt S, et al. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol. 1997;28:1039-1045.
16. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 1997;16:1-9.
17. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357-366.
18. Cameron RI, Ashe P, O'Rourke DM, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22:272-276.
19. Ohta Y, Suzuki T, Shiokawa A, et al. Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2005;24:239-245.
20. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281-294.
21. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36:195-201.
22. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001;38:403-408.
23. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2001;20:346-352.
24. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206-211.
25. Loo KT, Leung AK, Chan JK. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Histopathology. 1995 27:388-390.
26. Bamberger AM, Ivell R, Balvers M, et al. Relaxin-like factor (RLF): a new specific marker for Leydig cells in the ovary. Int J Gynecol Pathol. 1999;18:163-168.
27. McCluggage WG, Maxwell P. Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. Histopathology. 1999;35:216-220.
28. McCluggage WG, Maxwell P, Sloan JM. Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin. Hum Pathol. 1997;28:1034-1038.
29. Stewart CJ, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology. 1997;31:67-74.
30. Costa MJ, Ames PF, Walls J, et al. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective, diagnostic tool. Hum Pathol. 1997;28:1247-1254.
31. Kommoss F, Oliva E, Bhan AK, et al. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol. 1998;11:656-664.
32. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29:840-845.
33. Riopel MA, Perlman EJ, Seidman JD, et al. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol. 1998;17:46-53.
34. Rishi M, Howard LN, Bratthauer GL, et al. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 1997;21:583-589.
35. Pelkey TJ, Frierson HF Jr, Mills SE, et al. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol. 1998;17:97-105.
36. Guerrieri C, Franlund B, Malmstrom H, et al. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int J Gynecol Pathol. 1998;17:266-271.
37. Yao DX, Soslow RA, Hedvat CV, et al. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol Morphol. 2003;11:244-249.
38. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584-590.
39. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26:1477-1483.
40. Shah VI, Freites ON, Maxwell P, et al. Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms. J Clin Pathol. 2003;56:221-224.
41. Flemming P, Wellmann A, Maschek H, et al. Monoclonal antibodies against inhibin represent key markers of adult granulose cell tumors of the ovary even in their metastases: a report of three cases with late metastasis, being previously misinterpreted as hemangiopericytoma. Am J Surg Pathol. 1995;19:927-933.
42. Costa MJ, De Rose PB, Roth LM, et al. Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value. Hum Pathol. 1994;25:60-66.
43. McCluggage WG. Immunoreactivity of ovarian juvenile granulosa cell tumours with epithelial membrane antigen. Histopathology. 2005;46:235-236.
44. Otis CN, Powell JL, Barbuto D, et al. Intermediate filamentous proteins in adult granulosa cell tumors: an immunohistochemical study of 25 cases. Am J Surg Pathol. 1992;16:962-968.
45. Czernobilsky B, Moll R, Levy R, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of human ovary. Eur J Cell Biol. 1985;37:175-190.
46. Oliva E. CD10 expression in the female genital tract: does it have useful diagnostic applications? Adv Anat Pathol. 2004;11:310-315.
47. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
48. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
49. Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol. 2004;23:119-122.
50. Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003 22:374-377.
51. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004;12:122-126.
52. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-99.
53. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-545.
54. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441.
55. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch. 2001;435:181-191.
56. Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues and benign and neoplastic lesions of the female genital tract. Am J Pathol. 1999;155:1047-1050.
57. Ordonez NG. Transitional cell carcinomas of the ovary and bladder are phenotypically different. Histopathology. 2000;36:433-438.
58. McCluggage WG. Ovarian neoplasms composed of small round cells: a review. Adv Anat Pathol. 2004;11:288-296.
59. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23:330-336.
60. Ordonez NG. Desmoplastic small round cell tumor, II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol. 1998;22:1314-1327.
61. Eichhorn JH, Young RH, Scully RE. Primary ovarian small cell carcinoma of pulmonary type: a clinicopathologic, immunohistologic and flow cytometric analysis of 11 cases. Am J Surg Pathol. 1992;16:926-938.
62. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000;24:1657-1662.
63. Rossi S, Orvieto E, Furlanetto A, et al. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol. 2004;17:547-552.
64. Gupta D, Deavers MT, Silva EG, et al. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol. 2004;28:771-780.
65. Deavers MT, Malpica A, Ordonez NG, et al. Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol. 2003;22:162-167.
66. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary adenocarcinoma of the ovary and peritoneum. Histopathology. 2002;40:237-244.
67. Attanoos RL, Griffin A, Gibbs A. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and bcl-2. Histopathology. 2003;43:231-238.
68. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28:1341-1346.
69. Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): immunohistochemical evidence in support of a Wolffian origin. Hum Pathol. 1999;30:856-863.
70. Tiltman AJ, Allard U. Female adnexal tumours of probable Wolffian origin: an immunohistochemical study comparing tumours, mesonephric remnants and paramesonephric derivatives. Histopathology. 2001;38:237-242.